Summary
Protein-protein interactions (PPIs) control all cellular processes relevant to health and disease, hence an outstanding challenge in chemical biology is to develop generic approaches for PPI inhibition. Such inhibitors (or chemical probes) represent unique tools to understand biological processes and starting points for drug discovery, for treatment of multiple illnesses for which effective treatments don’t currently exist e.g. cancer.
SHAPPI will allow Zsofia Hegedus (the fellow) to join the laboratory of Andrew Wilson (host supervisor) at the University of Leeds (Host) and develop research expertise in the area of inhibiting protein-protein interactions. In doing so, she will (a) enhance her prospects to become an independent academic group leader and (b) address the need to train researchers in this key area of chemical biology and (c) develop cutting edge methods that advance peptidomimetic approaches for inhibition of protein-protein interactions. Scaffold hybridization will allow the combination of molecular scaffolds capable of hot spot mimicry with molecules that influence selectivity or potency. In combination with reversible chemistry this will allow generation of dynamic combinatorial libraries of rapid identification of selective and potent inhibitors. The fellowship will explore proteomimetic-peptide conjugates and peptide-small molecule dynamic combinatorial libraries to accelerate development of selective PPI inhibitors using two model interactions; HIF-1α/p300 and BID/BAX, both of which represent important targets for anticancer therapy.
SHAPPI will allow Zsofia Hegedus (the fellow) to join the laboratory of Andrew Wilson (host supervisor) at the University of Leeds (Host) and develop research expertise in the area of inhibiting protein-protein interactions. In doing so, she will (a) enhance her prospects to become an independent academic group leader and (b) address the need to train researchers in this key area of chemical biology and (c) develop cutting edge methods that advance peptidomimetic approaches for inhibition of protein-protein interactions. Scaffold hybridization will allow the combination of molecular scaffolds capable of hot spot mimicry with molecules that influence selectivity or potency. In combination with reversible chemistry this will allow generation of dynamic combinatorial libraries of rapid identification of selective and potent inhibitors. The fellowship will explore proteomimetic-peptide conjugates and peptide-small molecule dynamic combinatorial libraries to accelerate development of selective PPI inhibitors using two model interactions; HIF-1α/p300 and BID/BAX, both of which represent important targets for anticancer therapy.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/749012 |
Start date: | 01-05-2017 |
End date: | 30-04-2019 |
Total budget - Public funding: | 183 454,80 Euro - 183 454,00 Euro |
Cordis data
Original description
Protein-protein interactions (PPIs) control all cellular processes relevant to health and disease, hence an outstanding challenge in chemical biology is to develop generic approaches for PPI inhibition. Such inhibitors (or chemical probes) represent unique tools to understand biological processes and starting points for drug discovery, for treatment of multiple illnesses for which effective treatments don’t currently exist e.g. cancer.SHAPPI will allow Zsofia Hegedus (the fellow) to join the laboratory of Andrew Wilson (host supervisor) at the University of Leeds (Host) and develop research expertise in the area of inhibiting protein-protein interactions. In doing so, she will (a) enhance her prospects to become an independent academic group leader and (b) address the need to train researchers in this key area of chemical biology and (c) develop cutting edge methods that advance peptidomimetic approaches for inhibition of protein-protein interactions. Scaffold hybridization will allow the combination of molecular scaffolds capable of hot spot mimicry with molecules that influence selectivity or potency. In combination with reversible chemistry this will allow generation of dynamic combinatorial libraries of rapid identification of selective and potent inhibitors. The fellowship will explore proteomimetic-peptide conjugates and peptide-small molecule dynamic combinatorial libraries to accelerate development of selective PPI inhibitors using two model interactions; HIF-1α/p300 and BID/BAX, both of which represent important targets for anticancer therapy.
Status
CLOSEDCall topic
MSCA-IF-2016Update Date
28-04-2024
Images
No images available.
Geographical location(s)